The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,480
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,009
Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy
Song, X., Liu, C., Wang, N., Huang, H., He, S., Gong, C., & Wei, Y. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.010 · Cited by 217
CRISPR‐Cas Biochemistry and CRISPR‐Based Molecular Diagnostics
Weng, Z., You, Z., Yang, J., Mohammad, N., Lin, M., Wei, Q., Gao, X., & Zhang, Y. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202214987 · Cited by 213
Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq
Kim, D., Kim, S., Kim, S., Park, J., & Kim, J.-S. (2016) · Genome Research · doi:10.1101/gr.199588.115 · Cited by 208
CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems
Jiang, W., & Marraffini, L. A. (2015) · Annual Review of Microbiology · doi:10.1146/annurev-micro-091014-104441 · Cited by 219
Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9
Koo, T., Lee, J., & Kim, J. (2015) · Molecules and Cells · doi:10.14348/molcells.2015.0103 · Cited by 213
Synthetic Biology—The Synthesis of Biology
Ausländer, S., Ausländer, D., & Fussenegger, M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201609229 · Cited by 210
A Thermostable Cas9 with Increased Lifetime in Human Plasma
Harrington, L. B., Paez-Espino, D., Staahl, B. T., Chen, J. S., Ma, E., Kyrpides, N. C., & Doudna, J. A. (2017) · Nature Communications · doi:10.1038/s41467-017-01408-4 · Cited by 205
Modern Trends in Plant Genome Editing: An Inclusive Review of the CRISPR/Cas9 Toolbox
Razzaq, A., Saleem, F., Kanwal, M., Mustafa, G., Yousaf, S., Arshad, H. M. I., Hameed, M. K., Khan, M. S., & Joyia, F. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164045 · Cited by 216
Engineered materials for in vivo delivery of genome-editing machinery
Tong, S., Moyo, B., Lee, C. M., Leong, K. W., & Bao, G. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0145-9 · Cited by 208
Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study
Kaminski, R., Bella, R., Yin, C., Otte, J., Ferrante, P., Gendelman, H. E., Li, H., Booze, R. M., Gordon, J., Hu, W., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.41 · Cited by 213
Li, J., Manghwar, H., Sun, L., Wang, P., Wang, G., Sheng, H., Zhang, J., Liu, H., Qin, L., Rui, H., et al. (2018) · Plant Biotechnology Journal · doi:10.1111/pbi.13020 · Cited by 211
Structural Plasticity of PAM Recognition by Engineered Variants of the RNA-Guided Endonuclease Cas9
Anders, C., Bargsten, K., & Jinek, M. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.020 · Cited by 201
Challenges in CRISPR/CAS9 delivery: potential roles of nonviral vectors
Li, L., He, Z.-Y., Wei, X.-W., Gao, G.-P., & Wei, Y.-Q. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.069 · Cited by 202
Abadi, S., Yan, W. X., Amar, D., & Mayrose, I. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005807 · Cited by 208
Self-citationAllele-specific gene editing prevents deafness in a model of dominant progressive hearing loss
György, B., Nist-Lund, C. A., Pan, B., Asai, Y., Karavitaki, K. D., Kleinstiver, B. P., Garcia, S. P., Zaborowski, M. P., Solanes, P., Spataro, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0500-9 · Cited by 196
Various Aspects of a Gene Editing System—CRISPR–Cas9
Janik, E., Niemcewicz, M., Ceremuga, M., Krzowski, Ł., Saluk, J., & Bijak, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249604 · Cited by 223
A generic strategy for CRISPR-Cas9-mediated gene tagging
Lackner, D. H., Carré, A., Guzzardo, P. M., Banning, C., Mangena, R., Henley, T., Oberndorfer, S., Gapp, B. V., Nijman, S. M. B., Brummelkamp, T. R., et al. (2015) · Nature Communications · doi:10.1038/ncomms10237 · Cited by 199
Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases
Xu, C., Lu, Z.-D., Luo, Y., Liu, Y., Cao, Z., Shen, S., Li, H., Liu, J., Chen, K., Chen, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06522-5 · Cited by 199
Davis, J. R., Wang, X., Witte, I. P., Huang, T. P., Levy, J. M., Raguram, A., Banskota, S., Seidah, N. G., Musunuru, K., & Liu, D. R. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00911-4 · Cited by 199
Early and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
CRISPR-Cas Tools and Their Application in Genetic Engineering of Human Stem Cells and Organoids
Hendriks, D. F. G., Clevers, H. C., & Artegiani, B. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.10.014 · Cited by 202
Development of Light‐Activated CRISPR Using Guide RNAs with Photocleavable Protectors
Jain, P., Ramanan, V., Schepers, A. G., Dalvie, N. S., Panda, A., Fleming, H. E., & Bhatia, S. N. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201606123 · Cited by 190
A CRISPR toolbox to study virus–host interactions
Puschnik, A. S., Majzoub, K., Ooi, Y. S., & Carette, J. E. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.29 · Cited by 185
Hyperexcitable arousal circuits drive sleep instability during aging
Li, S., Damonte, V. M., Chen, C., Wang, G. X., Kebschull, J. M., Yamaguchi, H., Bian, W.-J., Purmann, C., Pattni, R., Urban, A. E., et al. (2022) · Science · doi:10.1126/science.abh3021 · Cited by 203
Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
Gori, J. L., Hsu, P. D., Maeder, M. L., Shen, S., Welstead, G. G., & Bumcrot, D. A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.074 · Cited by 200
Viral vectors for therapy of neurologic diseases
Choudhury, S. R., Hudry, E., Maguire, C. A., Sena-Esteves, M., Breakefield, X. O., & Grandi, P. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.02.013 · Cited by 190
Ye, L., Wang, J., Tan, Y., Beyer, A. I., Xie, F., Muench, M. O., & Kan, Y. W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612075113 · Cited by 197
On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals
Mojica, F. J. M., & Montoliu, L. (2016) · Trends in Microbiology · doi:10.1016/j.tim.2016.06.005 · Cited by 212
Chen, B., Hu, J., Almeida, R., Liu, H., Balakrishnan, S., Covill‐Cooke, C., Lim, W. A., & Huang, B. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1533 · Cited by 190
Engineering of high-precision base editors for site-specific single nucleotide replacement
Tan, J., Zhang, F., Karcher, D., & Bock, R. (2019) · Nature Communications · doi:10.1038/s41467-018-08034-8 · Cited by 198
Self-citationSynthetic CRISPR RNA-Cas9–guided genome editing in human cells
Rahdar, M., McMahon, M. A., Prakash, T. P., Swayze, E. E., Bennett, C. F., & Cleveland, D. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520883112 · Cited by 184
In vivo genome editing improves motor function and extends survival in a mouse model of ALS
Gaj, T., Ojala, D. S., Ekman, F. K., Byrne, L. C., Limsirichai, P., & Schaffer, D. V. (2017) · Science Advances · doi:10.1126/sciadv.aar3952 · Cited by 185
Precision genome editing in the CRISPR era
Salsman, J., & Dellaire, G. (2016) · Biochemistry and Cell Biology · doi:10.1139/bcb-2016-0137 · Cited by 193
CRISPR Correction of Duchenne Muscular Dystrophy
Min, Y.-L., Bassel‐Duby, R., & Olson, E. N. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-010451 · Cited by 193
CRISPR-Cas systems for diagnosing infectious diseases
Kostyusheva, A., Brezgin, S., Babin, Y. Y., Vasilyeva, I., Glebe, D., Kostyushev, D. S., & Chulanov, V. (2021) · Methods · doi:10.1016/j.ymeth.2021.04.007 · Cited by 197
RNA-dependent RNA targeting by CRISPR-Cas9
Strutt, S. C., Torrez, R. M., Kaya, E., Negrete, O. A., & Doudna, J. A. (2018) · eLife · doi:10.7554/elife.32724 · Cited by 186
Precise insertion and guided editing of higher plant genomes using Cpf1 CRISPR nucleases
Begemann, M. B., Gray, B. N., January, E., Gordon, G. C., He, Y., Liu, H., Wu, X., Brutnell, T. P., Mockler, T. C., & Oufattole, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-11760-6 · Cited by 183
Self-citationOrganelle-level precision with next-generation targeting technologies
Saminathan, A., Zajac, M. A., Anees, P., & Krishnan, Y. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00396-8 · Cited by 194
Highly efficient genome editing by CRISPR-Cpf1 using CRISPR RNA with a uridinylate-rich 3′-overhang
Moon, S. B., Lee, J. M., Kang, J. G., Lee, N.-E., Ha, D.-I., Kim, D. Y., Kim, S. H., Yoo, K., Kim, J., Kim, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06129-w · Cited by 187
Development of CRISPR-Cas systems for genome editing and beyond
Zhang, F. (2019) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583519000052 · Cited by 188
Self-citationYe, Y., Zhang, X., Xie, F., Xu, B., Xie, P., Yang, T., Shi, Q., Zhang, C., Zhang, Y., Chen, J., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00427h · Cited by 184
Tian, T., Qiu, Z., Jiang, Y., Zhu, D., & Zhou, X. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113701 · Cited by 180
Deciphering, Communicating, and Engineering the CRISPR PAM
Leenay, R. T., & Beisel, C. L. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.024 · Cited by 180
CRISPR–Cas: a tool for cancer research and therapeutics
Yin, H., Xue, W., & Anderson, D. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0166-8 · Cited by 185
Li, C., Brant, E. J., Budak, H., & Zhang, B. (2021) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2100009 · Cited by 191
Balboa, D., Weltner, J., Eurola, S., Trokovic, R., Wartiovaara, K., & Otonkoski, T. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.08.001 · Cited by 178
Guan, Y., Ma, Y., Li, Q., Sun, Z., Ma, L., Wu, L., Wang, L., Zeng, L., Shao, Y., Chen, Y., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506039 · Cited by 179
RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors
Thakore, P. I., Kwon, J. B., Nelson, C. E., Rouse, D. C., Gemberling, M. P., Oliver, M. L., & Gersbach, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-04048-4 · Cited by 181
Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome
Santiago‐Fernández, O., Osorio, F. G., Quesada, V., Rodríguez, F. J., Basso, S., Maeso, D., Rolas, L., Barkaway, A., Nourshargh, S., Folgueras, A. R., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0338-6 · Cited by 176
Recent Progress in CRISPR/Cas9 Technology
Mei, Y., Wang, Y., Chen, H., Sun, Z. S., & Ju, X.-D. (2016) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.01.001 · Cited by 148
A catalogue of biochemically diverse CRISPR-Cas9 orthologs
Gasiūnas, G., Young, J. K., Karvelis, T., Kazlauskas, D., Urbaitis, T., Jasnauskaitė, M., Grusyte, M. M., Paulraj, S., Wang, P.-H., Hou, Z., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19344-1 · Cited by 181
Multidimensional control of therapeutic human cell function with synthetic gene circuits
Li, H.-S., Israni, D. V., Gagnon, K. A., Gan, K. A., Raymond, M. H., Sander, J. D., Roybal, K. T., Joung, J. K., Wong, W. W., & Khalil, A. S. (2022) · Science · doi:10.1126/science.ade0156 · Cited by 187
Precision genome editing using cytosine and adenine base editors in mammalian cells
Huang, T. P., Newby, G. A., & Liu, D. R. (2021) · Nature Protocols · doi:10.1038/s41596-020-00450-9 · Cited by 175
Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update
Sun, C., Shen, L., Zhang, Z., & Xie, X. (2020) · Genes · doi:10.3390/genes11080837 · Cited by 187
Drug delivery systems for CRISPR-based genome editors
Madigan, V. J., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 193
Self-citationAdeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery
Nidetz, N. F., McGee, M. C., Tse, L. V., Li, C., Cong, L., Li, Y., & Huang, W. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107453 · Cited by 174
Self-citationCRISPR/Cas9: A powerful tool for crop genome editing
Song, G., Jia, M., Chen, K., Kong, X., Khattak, B., Xie, C., Li, A., & Mao, L. (2016) · The Crop Journal · doi:10.1016/j.cj.2015.12.002 · Cited by 180
Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer
Jeong, S., Kim, H.-B., Kim, M., Lee, J.-M., Lee, J. H., Kim, J., Kim, J. W., Park, W., Kim, S., Kim, J. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95802 · Cited by 176
CRISPR-Cas9 off-targeting assessment with nucleic acid duplex energy parameters
Alkan, F., Wenzel, A., Anthon, C., Havgaard, J. H., & Gorodkin, J. (2018) · Genome biology · doi:10.1186/s13059-018-1534-x · Cited by 174
Evaluating and enhancing target specificity of gene-editing nucleases and deaminases
Kim, D., Luk, K., Wolfe, S. A., & Kim, J.-S. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111730 · Cited by 171
Rasul, M. F., Hussen, B. M., Salihi, A. B., Ismael, B. S., Jalal, P. J., Zanichelli, A., Jamali, E., Baniahmad, A., Ghafouri‐Fard, S., Basiri, A., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01487-4 · Cited by 187
Directed evolution of adeno-associated virus for efficient gene delivery to microglia
Lin, R., Zhou, Y., Yan, T., Wang, R., Li, H., Wu, Z., Zhang, X., Zhou, X., Zhao, F., Zhang, L., et al. (2022) · Nature Methods · doi:10.1038/s41592-022-01547-7 · Cited by 171
The RNA-Binding Protein PUM2 Impairs Mitochondrial Dynamics and Mitophagy During Aging
D’Amico, D., Mottis, A., Potenza, F., Sorrentino, V., Li, H., Romani, M., Lemos, V., Schoonjans, K., Zamboni, N., Knott, G., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.11.034 · Cited by 159
Yamada, M., Watanabe, Y., Gootenberg, J. S., Hirano, H., Ran, F. A., Nakane, T., Ishitani, R., Zhang, F., Nishimasu, H., & Nureki, O. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.02.007 · Cited by 170
Self-citationLatella, M. C., Salvo, M. T. D., Cocchiarella, F., Benati, D., Grisendi, G., Comitato, A., Marigo, V., & Recchia, A. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.92 · Cited by 168
A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene
Kemaladewi, D. U., Bassi, P. S., Erwood, S., Al-Basha, D., Gawlik, K. I., Lindsay, K., Hyatt, E., Kember, R., Place, K. M., Marks, R. M., et al. (2019) · Nature · doi:10.1038/s41586-019-1430-x · Cited by 168
Holme, I. B., Gregersen, P. L., & Brinch‐Pedersen, H. (2019) · Frontiers in Plant Science · doi:10.3389/fpls.2019.01468 · Cited by 182
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA
Wolter, J. M., Mao, H., Fragola, G., Simon, J. M., Krantz, J. L., Bazick, H., Oztemiz, B., Stein, J. L., & Zylka, M. J. (2020) · Nature · doi:10.1038/s41586-020-2835-2 · Cited by 171
Characterizing a thermostable Cas9 for bacterial genome editing and silencing
Mougiakos, I., Mohanraju, P., Bosma, E. F., Vrouwe, V., Finger‐Bou, M., Naduthodi, M. I. S., Gussak, A., Brinkman, R. B. L., van Kranenburg, R., & John van der, O. O. S. T. (2017) · Nature Communications · doi:10.1038/s41467-017-01591-4 · Cited by 165
Genome surgery using Cas9 ribonucleoproteins for the treatment of age-related macular degenerationPreprint
Kim, K., Park, S. W., Kim, J. H., Lee, S. H., Kim, D., Koo, T., Kim, K.-E., Kim, J. H., & Kim, J. (2017) · Genome Research · doi:10.1101/gr.219089.116 · Cited by 170
Gene targeting, genome editing: from Dolly to editors
Tan, W. S., Proudfoot, C., Lillico, S. G., & Whitelaw, B. (2016) · Transgenic Research · doi:10.1007/s11248-016-9932-x · Cited by 163
Zhang, Y., Yin, C., Zhang, T., Li, F., Yang, W., Kaminski, R., Fagan, P. R., Putatunda, R., Young, W., Khalili, K., et al. (2015) · Scientific Reports · doi:10.1038/srep16277 · Cited by 174
Limpitikul, W. B., Dick, I. E., Tester, D. J., Boczek, N. J., Limphong, P., Yang, W., Choi, M. H., Babich, J., DiSilvestre, D. A., Kanter, R. J., et al. (2016) · Circulation Research · doi:10.1161/circresaha.116.309283 · Cited by 163
Juszczuk‐Kubiak, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052655 · Cited by 177
Exploring the potential of genome editing CRISPR-Cas9 technology
Singh, V., Braddick, D., & Dhar, P. K. (2016) · Gene · doi:10.1016/j.gene.2016.11.008 · Cited by 172
CRISPR-Cas for genome editing: Classification, mechanism, designing and applications
Bhatia, S. K., ., P., & Yadav, S. K. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124054 · Cited by 178
In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation
Moreno, A. M., Fu, X., Zhu, J., Katrekar, D., Shih, Y.-R. V., Marlett, J., Cabotaje, J., Tat, J., Naughton, J., Lisowski, L., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.017 · Cited by 159
Ekman, F. K., Ojala, D. S., Adil, M. M., Zapana, P. A. L., Schaffer, D. V., & Gaj, T. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.07.009 · Cited by 165
Structural basis for the altered PAM specificities of engineered CRISPR-cas9
Hirano, S., Nishimasu, H., Ishitani, R., & Nureki, O. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.018 · Cited by 152
Chen, F., Ding, X. L., Feng, Y., Seebeck, T., Jiang, Y., & Davis, G. D. (2017) · Nature Communications · doi:10.1038/ncomms14958 · Cited by 156
Advances in Engineering the Fly Genome with the CRISPR-Cas System
Bier, E., Harrison, M. M., O’Connor-Giles, K. M., & Wildonger, J. (2018) · Genetics · doi:10.1534/genetics.117.1113 · Cited by 155
Shao, J., Wang, M., Yu, G., Zhu, S., Yu, Y., Heng, B. C., Wu, J., & Ye, H. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802448115 · Cited by 154
Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges
Luther, D. C., Lee, Y. W., Nagaraj, H., Scaletti, F., & Rotello, V. M. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1517746 · Cited by 162
Kouranova, E. V., Forbes, K. P., Zhao, G., Warren, J., Bartels, A., Wu, Y., & Cui, X. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.009 · Cited by 151
Dual gene activation and knockout screen reveals directional dependencies in genetic networks
Boettcher, M., Tian, R., Blau, J. A., Markegard, E., Wagner, R. T., Wu, D., Mo, X., Biton, A., Zaitlen, N., Fu, H., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4062 · Cited by 153
CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research
Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 167
Engineered Viruses as Genome Editing Devices
Chen, X., & Gonçalves, M. A. F. V. (2015) · Molecular Therapy · doi:10.1038/mt.2015.164 · Cited by 154
Revolutionizing plant biology: multiple ways of genome engineering by CRISPR/Cas
Schiml, S., & Puchta, H. (2016) · Plant Methods · doi:10.1186/s13007-016-0103-0 · Cited by 151
CRISPR/Cas9 in insects: Applications, best practices and biosafety concerns
Taning, C. N. T., Eynde, B. V., Yu, N., Ma, S., & Smagghe, G. J. (2017) · Journal of Insect Physiology · doi:10.1016/j.jinsphys.2017.01.007 · Cited by 158
Ortinski, P. I., O’Donovan, B., Dong, X., & Kantor, B. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.04.002 · Cited by 146
Genome-wide profiling of adenine base editor specificity by EndoV-seq
Liang, P., Xie, X., Zhi, S., Sun, H., Zhang, X., Chen, Y., Chen, Y., Xiong, Y., Ma, W., Liu, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07988-z · Cited by 148
Tóth, E., Varga, É., Kulcsár, P. I., Kocsis-Jutka, V., Krausz, S. L., Nyeste, A., Welker, Z., Huszár, K., Ligeti, Z., Tálas, A., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa110 · Cited by 147
Adeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 150
Chen, W., Zhang, Y., Yeo, W., Bae, T., & Ji, Q. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b13317 · Cited by 152
Fiaz, S., Ahmad, S., Noor, M. A., Wang, X., Younas, A., Riaz, A., Riaz, A., & Ali, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040888 · Cited by 146
Type II-C CRISPR-Cas9 Biology, Mechanism, and Application
Mir, A., Edraki, A., Lee, J., & Sontheimer, E. J. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00855 · Cited by 155
Kim, H. K., Lee, S., Kim, Y., Park, J., Min, S., Choi, J. W., Huang, T. P., Yoon, S., Liu, D. R., & Kim, H. H. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0505-1 · Cited by 145
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Dai, W.-J., Zhu, L., Yan, Z., Xu, Y., Wang, Q., & Lu, X. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.58 · Cited by 148
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
